G

GemPharmatech Co Ltd
SSE:688046

Watchlist Manager
GemPharmatech Co Ltd
SSE:688046
Watchlist
Price: 13.53 CNY -1.24% Market Closed
Market Cap: 5.5B CNY
Have any thoughts about
GemPharmatech Co Ltd?
Write Note

GemPharmatech Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GemPharmatech Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
GemPharmatech Co Ltd
SSE:688046
Total Equity
ÂĄ2.1B
CAGR 3-Years
48%
CAGR 5-Years
138%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Equity
ÂĄ54.7B
CAGR 3-Years
14%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Equity
ÂĄ13B
CAGR 3-Years
10%
CAGR 5-Years
34%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Equity
ÂĄ40.7B
CAGR 3-Years
7%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Equity
ÂĄ20.8B
CAGR 3-Years
7%
CAGR 5-Years
40%
CAGR 10-Years
39%
W
WuXi XDC Cayman Inc
HKEX:2268
Total Equity
ÂĄ5.5B
CAGR 3-Years
144%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GemPharmatech Co Ltd
Glance View

Market Cap
5.5B CNY
Industry
Life Sciences Tools & Services

GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

Intrinsic Value
21.04 CNY
Undervaluation 36%
Intrinsic Value
Price
G

See Also

What is GemPharmatech Co Ltd's Total Equity?
Total Equity
2.1B CNY

Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Total Equity amounts to 2.1B CNY.

What is GemPharmatech Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
138%

Over the last year, the Total Equity growth was 7%. The average annual Total Equity growth rates for GemPharmatech Co Ltd have been 48% over the past three years , 138% over the past five years .

Back to Top